Korea United Pharmaceutical agreed to expand market to South America with Teva

Published: 2014-04-02 11:20:35

Updated: 2014-04-02 11:20:35

On Mar 31, Korea United Pharmaceutical announced that they signed additional contract of Incrementally Modified Drug 'CLANZA CR Tab' in South American market with a global pharmaceutical company in Israel, Teva.

In Last February 2013, Korea United Pharmaceutical signed a contract with Teva and Eastern European countries including Russia. They signed an additional contract and agreed to expand ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.